Aardvark Therapeutics Faces Investor Lawsuit for Fraud
Investors' Trust on Shaky Grounds There it is, staring right back at investors: a securities fraud class action lawsuit against Aardvark Therapeutics. Not exactly the news a shareholder wants to digest over breakfast. If you’ve got skin in the game with Aardvark Therapeutics (NASDAQ: AARD), you might wanna keep reading. Hagens Berman Sobol Shapiro LLP, a name that's no...
Continue Reading